Drug Development/R&D

What would be the price for an orphan drug that generate rates of return no greater/smaller than the industry average? Is it reasonable?

In this paper, Sir Geoffrey Owen and Dr Michael Hopkins discuss ‘The UK Biotech Sector and Brexit: Past Performance and Future Prospects’.

Just published are two new reports that explore the use of real world evidence for coverage and formulary decisions. The publications represent 1) the background paper to the 2017 ICER Membership Policy Summit and 2) a follow up paper based on the discussion at the Summit.

OHE has just published a new briefing entitled ‘Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?’

OHE publishes a report assessing the capacity in South Korea for the collection and use of real-world data in health care.

OHE Lunchtime Seminar with Sir Geoffrey Owen and Professor Michael Hopkins. The biotech sector of the US has enjoyed a success that the UK sector has found difficult to match. Will the Brexit improve or damage UK's biotech sector prospects?

A new paper sets out an insurance model as part of a global solution to incentivise R&D for new antibiotics to tackle multi-drug resistance. It offers (i) a reasonable return on R&D; (ii) risk mitigation for payers, providers and manufacturers, (iii) stewardship by delinking revenues from volume of use, and (iv) conservation of antibiotic effectiveness by ensuring the continued availability of new antibiotics in the long-term.

The Structural Genomics Consortium Oxford, University of Oxford, in collaboration with OHE (Prof Adrian Towse) and Dr Jorge Mestre-Ferrandiz, is recruiting for a Postdoctoral Position in “The Economics of life sciences’ R&D”.

In November 2016 Professor Dame Sally Davies delivered the 23rd OHE Annual Lecture on the topic of: Ten Years of the NIHR: Achievements and Challenges for the Next Decade. The lecture is now available as a publication, available for download.

Without new antibiotics, more patients will die from previously treatable infections. A key issue is how the value of antibiotics can be appropriately assessed by payers and HTA bodies.

Pages

Subscribe to RSS - Drug Development/R&D